Please login to the form below

Not currently logged in
Email:
Password:

Sucampo moves on EU market

US pharmaceutical company, Sucampo, has launched a bid to compete in the European marketplace by filing a marketing authorisation application in Switzerland for its drug, Amitiza
US pharmaceutical company, Sucampo, has launched a bid to compete in the European marketplace by filing a marketing authorisation application (MAA) in Switzerland for its drug, Amitiza.

It has been developed for the treatment of chronic idiopathic constipation and is already available in the US. Sucampo hopes that it will soon be approved for use in Switzerland and is keen to build on what it has referred to as ëthe drug's success in the US' to extend its operations into the EU.

"We are systematically developing additional marketing opportunities outside the US," said Dr Ryuji Ueno, founder, chairman and CEO of Sucampo.

"This application is a continuation of these efforts as well as an ongoing expansion of our European operations."

The MAA has been submitted to SwissMedic, the regulatory body for medical products in Switzerland. The US Food and Drug Administration (FDA) first approved the drug for the treatment of chronic idiopathic constipation in adults in April 2006 and subsequently extended its uses for women suffering from irritable bowel syndrome (IBS) with constipation.

Nine other EU countries are currently reviewing MAAs for Amitiza, which were filed by Sucampo. Excluding the drug's marketing licence in the US, the company retains all commercial rights for the product in the whole of Europe and the rest of the world.

9th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Random42 Scientific Communication

Random42 is the world's leading medical animation company. Over the past 25 years we have produced core digital assets for...

Latest intelligence

How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...
Medopad: the up and coming unicorn transforming remote patient monitoring
Blue Latitude Health speaks to Medopad’s Martha Carruthers to learn how the start-up’s modular apps are helping patients with complex diseases....

Infographics